LitCovid-sentences  

PMC:7784786 / 16529-18065 JSONTXT 3 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T145 0-10 Sentence denotes Conclusion
T146 11-118 Sentence denotes In summary, in these severe and critically ill patients, itolizumab was able to reduce IL-6 concentrations.
T147 119-180 Sentence denotes Notably, itolizumab-related adverse events were not reported.
T148 181-282 Sentence denotes Patients with baseline IL-6 levels below 200 pg/ml, showed prompt clinical and radiological recovery.
T149 283-476 Sentence denotes We anticipate that the timely use of this anti-inflammatory antibody in combination with the appropriate antiviral and anticoagulant therapy could reduce the mortality associated with COVID-19.
T150 477-539 Sentence denotes The analysis of the complete-series will be published shortly.
T151 540-554 Sentence denotes Summary points
T152 555-667 Sentence denotes Inflammatory cytokine-release syndrome is associated with the progression of the coronavirus disease (COVID-19).
T153 668-751 Sentence denotes No current therapy has proven effective for the management of this syndrome so far.
T154 752-910 Sentence denotes Itolizumab is a humanized monoclonal antibody that recognizes human CD6 and its effect is associated with the reduction of pro-inflammatory cytokines release.
T155 911-1033 Sentence denotes We present three COVID-19 cases who developed severe respiratory distress together with multifocal interstitial pneumonia.
T156 1034-1110 Sentence denotes The patients were treated with itolizumab combined with antiviral therapies.
T157 1111-1193 Sentence denotes Itolizumab reduced circulating IL-6 concentrations in the three COVID-19 patients.
T158 1194-1286 Sentence denotes Two patients showed rapid ventilatory and radiological improvement and were fully recovered.
T159 1287-1339 Sentence denotes Itolizumab-related adverse events were not reported.
T160 1340-1536 Sentence denotes These cases show that the timely use of this anti-inflammatory antibody in combination with the appropriate antiviral and anticoagulant therapy could reduce the mortality associated with COVID-19.